Innovo Therapeutics

Innovo Therapeutics, founded in 2021, is a biotechnology startup based in the United States. The company is focused on innovating novel cancer treatments by eliminating cancer-causing proteins. Innovo Therapeutics is committed to addressing areas of high unmet medical need through the discovery and development of the next generation of protein degraders. The company possesses extensive experience in drug discovery and has developed a proprietary phenotypic screening platform, coupled with a powerful targeted protein degradation platform called TriNovo. Innovo Therapeutics’ competitive advantage lies in its differentiated drug discovery approach, which enables the rapid expansion of a high-quality, differentiated pipeline. The company holds worldwide exclusive rights to Rosmantuzumab, an anti-RSPO3 mAB, which is currently in a Phase 2 clinical program. Additionally, they are actively engaged in further pharma partnership discussions to advance their pipeline programs. The last investment in Innovo Therapeutics was a CNY100.00M Seed Round investment on 01 December 2023, with participation from notable investors such as CICC, Longmen Capital, Acusea/Huiyuan Capital, Ming Bioventures, and Qiandao Fund. The company aims to maximize its expertise, productivity, and efficiency by leveraging its US team's proven drug discovery experience and optimizing China’s rich pre-clinical resources and infrastructure to build a world-class, global biopharma company.